The molecular diagnostics cost of revenue for the third quarter was $8.3 million, compared to $7.6 million in the third quarter of fiscal 2007. This 9% increase on 55% revenue growth is due in part to the technology improvements and efficiency gains that the Company has made in its molecular diagnostics laboratory.The gross profit margin on the Company's molecular diagnostics business was 86% for the three months ended March 31, 2008, compared with an 80% gross profit margin from the same three month period in 2007.Net operating income for the Company's molecular diagnostics business increased to $27.7 million, a 47% net operating margin, in the third quarter of fiscal 2008. This result compares to $16.2 million, a 43% net operating margin, in the third quarter of fiscal 2007, representing a 71% increase in net operating profit."We continue to see strong topline and bottom-line growth in our molecular diagnostics business," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We are equally pleased with the progress we are making on the therapeutic side of the Company. We have completed the Phase 3 clinical trial of Flurizan ® in Alzheimer's disease and look forward to announcing the results in the near future."

No abstract

No abstract

No abstract

No abstract

Temperature profiles induced by a cw laser beam in a semiconductor are calculated. The calculation is done for an elliptical scanning beam and covers a wide range of experimental conditions. The limiting case of a circular beam is also studied. This calculation is developed in the particular cases of silicon and gallium arsenide, where the temperature dependence of the thermal conductivity has been taken into consideration. Using a cylindrical lens to produce an elliptical beam with an aspect ratio of 20, a 1-mm-wide area of an ion-implanted silicon wafer was annealed in a single scan. The experimental data are consistent with the extrapolation of solid-phase epitaxial regrowth rates to the calculated laser-induced temperatures.

Support for open science is growing, but motivating researchers to participate in open science can be challenging. This in-depth qualitative study draws on interviews with researchers and staff at the Montreal Neurological Institute and Hospital during the development of its open science policy. Using thematic content analysis, we explore attitudes toward open science, the motivations and disincentives to participate, the role of patients, and attitudes to the eschewal of intellectual property rights. To be successful, an open science policy must clearly lay out expectations, boundaries and mechanisms by which researchers can engage, and must be shaped to explicitly support their values and those of key partners, including patients, research participants and industry collaborators.

This month's debate examines whether the current patent system is crucial for stimulating health research or whether it is stifling biomedical research and impeding medical care.